West Pharmaceutical Services (WST) Liabilities and Shareholders Equity (2009 - 2026)

West Pharmaceutical Services has disclosed Liabilities and Shareholders Equity across 18 years of filings, most recently posting $4.1 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $4.1 billion, up 13.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.4 billion (up 13.95% YoY), and the FY2025 annual result was $4.3 billion, up 17.2% from the prior year.
• Liabilities and Shareholders Equity came in at $4.1 billion for Q1 2026 at West Pharmaceutical Services, down from $4.3 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $4.3 billion in Q4 2025 to a low of $3.3 billion in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $3.7 billion (2023), against an average of $3.7 billion.
• Across the five-year window, Liabilities and Shareholders Equity gained 20.26% in 2022 and decreased 4.91% in 2024, its largest moves.
• West Pharmaceutical Services' Liabilities and Shareholders Equity stood at $3.6 billion in 2022, then climbed by 5.88% to $3.8 billion in 2023, then slipped by 4.86% to $3.6 billion in 2024, then increased by 17.2% to $4.3 billion in 2025, then retreated by 3.75% to $4.1 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $4.1 billion (Q1 2026), $4.3 billion (Q4 2025), and $4.1 billion (Q3 2025), per Business Quant data.